Results 131 to 140 of about 52,744 (222)

Multi-Focal Myasthenia Gravis

open access: yes, 2005
To report a multi-focal form of myasthenia gravis presenting with intermittent ...
Deborah I. Friedman, MD; Eric Logigian, MD; Josiah Chai, MD
core  

Myasthenia Gravis (video)

open access: yes, 2017
Myasthenia gravis is a disorder of neuromuscular transmission resulting from binding of autoantibodies to various components of the neuromuscular junction.
Matthew J. Thurtell
core  

A Novel Sequential Regimen of Efgartigimod and Telitacicept as Fast‐Acting Treatment for Impeding Crisis of MuSK‐MG

open access: yesImmunity, Inflammation and Disease, Volume 14, Issue 10, October 2026.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction. The muscle‐specific kinase (MuSK) antibody‐positive subtype often involves bulbar and respiratory muscles, conferring a high risk of myasthenic crisis. Method We report a very late‐onset MuSK‐MG case complicated by lung infection and acute heart failure,
Tianjiao Duan   +3 more
wiley   +1 more source

Plasma Exchange for Hantavirus Pulmonary Syndrome: A Mechanistic Case for an Untested Intervention

open access: yesJournal of Clinical Apheresis, Volume 41, Issue 5, October 2026.
ABSTRACT Hantavirus pulmonary syndrome (HPS) carries a case fatality rate of 35%–40% and has no approved pharmacologic treatment. Its pathophysiology is rooted in the plasma compartment: cytokines, viral antigens, immune complexes, and platelet‐binding glycoproteins circulate as drivers of immunopathologic endothelial injury, noncardiogenic pulmonary ...
Menatalla Nadim   +2 more
wiley   +1 more source

Myasthenia Gravis (abstract)

open access: yes, 2017
Myasthenia gravis is a disorder of neuromuscular transmission resulting from binding of autoantibodies to various components of the neuromuscular junction.
Matthew J. Thurtell
core  

Therapeutic Plasma Exchange in Pediatric Patients: A Multi‐Institutional Landscape Analysis

open access: yesJournal of Clinical Apheresis, Volume 41, Issue 5, October 2026.
ABSTRACT Pediatric evidence for therapeutic plasma exchange (TPE) is largely small, single‐center cohorts; there is no prior large‐scale age‐stratified outcomes assessment. Using the TriNetX US Collaborative Network, we identified 3744 patients ≤ 17 years old undergoing an index TPE procedure, stratified into four age groups (≤ 1, 2–5, 6–12, and 13–17 ...
Caitlin Raymond
wiley   +1 more source

Peripheral Blood Lymphocytosis Reflecting an Underlying Thymoma

open access: yes
American Journal of Hematology, Volume 101, Issue 10, Page 2652-2653, October 2026.
Léa Ousset   +2 more
wiley   +1 more source

von Willebrand Factor and ADAMTS13 Predict Therapeutic Efficacy and Severe Adverse Events in Advanced Hepatocellular Carcinoma Treated With Atezolizumab–Bevacizumab

open access: yesJGH Open, Volume 10, Issue 10, October 2026.
ABSTRACT Aims Atezolizumab combined with bevacizumab (AB therapy) is a standard first‐line treatment for advanced hepatocellular carcinoma (HCC). However, clinically useful biomarkers for predicting therapeutic efficacy and severe adverse events (AEs) remain limited.
Naoki Nishimura   +12 more
wiley   +1 more source

Myasthenia Gravis - Spontaneous Eye Movements

open access: yes, 1980
Clinical Signs: spontaneous eye movements (upward deviations). 21 year old woman with myasthenia and hyperthyearoidism for 2 years; eyes show marked ptosis and ophthalmoplegia.
David G. Cogan, MD (1908-1993)
core  

Myeloma‐Associated Sporadic Late‐Onset Nemaline Myopathy, Successfully Treated with Daratumumab Based Induction and Autologous Stem Cell Transplantation: A Case Report

open access: yeseJHaem, Volume 7, Issue 5, October 2026.
ABSTRACT Sporadic late‐onset nemaline myopathy (SLONM) is a rare, acquired myopathy often associated with monoclonal gammopathy. We report a 48‐year‐old man presenting with progressive proximal and truncal muscle weakness in whom SLONM associated with smoldering myeloma was highly suspected.
Kenji Moriwaki   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy